Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Women's Health Initiative (WHI)
NCT00000611Phase 3Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Primary completion
- Mar 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 3, randomised, double-blind trial of conjugated estrogens, medroxyprogesterone acetate, calcium carbonate and vitamin d in cardiovascular disease (CVD), osteoporosis and colorectal cancer (CRC) (8 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Coronary Heart Disease at 8.5 years, Invasive Breast Cancer at 8.5 years and 1 more. Status: completed.
02
Drugs
conjugated estrogensmedroxyprogesterone acetatecalcium carbonatevitamin d
03
Conditions
cardiovascular disease (CVD)osteoporosiscolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00000611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000611.